CD274 and non-small cell lung carcinoma: Our findings demonstrate that the presence of mTLS predicts a better outcome in patients with NSCLC treated with immunotherapy, regardless of PD-L1 expression (Figures S2E–S2J), underscoring mTLS status as a robust independent biomarker for patient stratification and prognosis.